<img alt="" src="https://secure.perk0mean.com/184504.png" style="display:none;">

 

The Evolving Perception of Pharma - Part 2

About the Episode

Tune into today’s episode as we dive into part 2 of our discussion around the evolving perception of Pharma with Azadeh Nolan. Make sure you listen to part 1 to find out more about her experiences. Today, we get a glimpse behind the curtain on planning, developing, and executing trials in the pharmaceutical industry.

Kathleen kicks off this episode by asking about the by-in that is required for the parents of children involved in trials. How do they get the trust and messaging necessary? Azadeh speaks to looking at the impacts of the trials therapeutically, socially, and psychologically. While trust must be earned, we also must have the expectation that we will be continual learners.Parents’ trust is crucial in these trials to give their children the allergens that are otherwise deadly to them.

Continuing the conversation, Kathleen asks a second question, and it is all about the checks and balances in this industry. Learn about the post-market studies to ensure safety, and the desire to keep improving through continual monitoring and advancements. What systems exist to double check a trial and the data requirements? Listen in on their conversation as they chat about the vast number of drugs that are not approved, or that have been recalled due to this continued research. Once a drug is through the trial phase, what happens? They discuss the rigorous process and verification of efficacy that occurs. Kathleen also asks about the “black box” of clinical development. Azadeh discusses the concept and process of playing out all the outcomes and the possibility of having to start over if the outcomes are not advantageous. There are countless years of research behind the drugs we see at a pharmacy.

While the media and societal misconceptions play into our everyday thinking about these topics, Azadeh shares what she thinks needs redefined. Learn about the power of data and why we should not expect perfection. It is alright for things to change, Azadeh reminds listeners that it is just biology, working towards perfection. As the conversation draws to a close, they chat about where are we headed and what have we done right so far. See the empathy and emphasis on humanity that proves a strength in today’s world. We have done it all together!

See Who's Talking

LIBBI RICKENBACHER

VP, Marketing and Partnerships

Libbi Rickenbacher, Vice President of Marketing and Partnerships at 4G Clinical, brings extensive industry experience across clinical research, commercial strategy, brand leadership, and partnership development. She leads global marketing and strategic partnership initiatives with a focus on positioning 4G Clinical for growth, strengthening market presence, and building meaningful industry collaboration. At 4G Clinical, Libbi is responsible for shaping brand strategy, advancing thought leadership, driving go-to-market execution, and developing partnerships that support innovation across the clinical trial ecosystem. Libbi holds a BA in psychology and neuroscience and a PhD in neuroscience.

AZADEH NOLAN

Global Head of Supply Chain, Mirador Therapeutics

Azadeh is a true Clinical Supplies pioneer with nearly 20 years of experience in pharma, dedicated to and with continuous accomplishments building and growing the industry’s Clinical Supply Chain Operations landscape as it’s seen today.

Subscribe to our podcast